Kiromic Biopharma Acquires InSilico Solutions

Illumina Acquires SomaLogic from Standard BioTools

January 30, 2026

Healthcare Services

Illumina, Inc. completed its acquisition of SomaLogic, adding data-driven proteomics technology to expand its multiomics portfolio. The deal was for $350 million in upfront cash at closing, plus up to $75 million in near-term performance-based milestones/royalties, with Illumina expecting to fund the transaction with cash on hand.

Kite (a Gilead Company) to Acquire Interius BioTherapeutics

August 21, 2025

Biotechnology

Kite, a Gilead company, entered into a definitive agreement to acquire Interius BioTherapeutics for $350 million in cash. The acquisition is intended to advance Kite’s in vivo CAR T-cell therapy platform by incorporating Interius’s integrating in vivo platform, delivered via a single intravenous infusion.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

QuartzBio (Precision for Medicine) Acquires SolveBio

January 24, 2023

Cloud & SaaS

QuartzBio, a business unit of Precision for Medicine, has acquired SolveBio and integrated its enterprise biomarker and genomic data management platform into QuartzBio’s end-to-end SaaS suite. The acquisition expands QuartzBio’s capabilities for sample inventory, biomarker data management and enterprise-level visibility to better serve pharmaceutical and biotech clients in clinical research and development.

Moderna Acquires OriCiro Genomics K.K. for $85 Million

January 5, 2023

Biotechnology

Moderna has entered into a definitive agreement to acquire OriCiro Genomics K.K. for $85 million. The deal is intended to add cell-free DNA synthesis and amplification technologies that complement Moderna’s mRNA manufacturing expertise and accelerate its R&D.

VeriSIM Life Acquires Molomics Biotech

May 11, 2022

Biotechnology

VeriSIM Life, an AI-driven virtual drug development company based in San Francisco, has acquired Molomics Biotech SL, a Barcelona-based AI-enabled drug discovery firm. The acquisition integrates Molomics' AI + Human Collective Intelligence discovery technology into VeriSIM's BIOiSIM platform to accelerate and improve success rates in drug discovery, including work on Parkinson's disease.